M ultifocal motor neuropathy (MMN) is a rare neuropathy that is often treatable with immunomodulatory therapy if diagnosed early. However, accurate diagnosis is difficult due to a significant overlap of symptoms with other neurological conditions, such as amyotrophic lateral sclerosis (ALS). Evidence of immunoglobulin M (IgM) anti-ganglioside GM1 antibodies and electrodiagnostic findings of conduction block are useful diagnostic criteria for MMN but are not universal findings. This review explores the differential diagnosis of MMN and ALS and discusses three cases of MMN initially diagnosed as ALS, in which the correct diagnosis allowed effective treatment. These cases highlight the need for greater awareness of MMN among physicians.
Multifocal motor neuropathy (MMN) is a rare motor neuropathy with a reported prevalence range of 0.3-3 cases in 100,000. 1 It affects more males than females (2.7:1) and onset usually occurs before 50 years of age. 1 The disease can progress to permanent weakness and disability but it is not life-threatening or as disabling as amyotrophic lateral sclerosis (ALS, one of the motor neuron diseases). 2 MMN symptoms overlap with other motor-predominant diseases, such as chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), ALS and ALS variants (progressive muscular atrophy, flail arm/flail leg syndromes); this overlap can introduce diagnostic uncertainty.
Recognizing the significant overlap in the presentation of MMN and ALS is particularly important given that MMN is treatable, whereas ALS is rapidly fatal and non-treatable. The profound psychosocial impact of an ALS diagnosis is well established and includes grief, depression, anxiety, feelings of hopelessness and other negative, life-altering psychological effects. 3, 4 While MMN can be debilitating, it does not carry the same grave prognosis as ALS and offers the hope of treatment options.
ALS inexorably progresses, spreading to involve multiple different motor functions before eventually resulting in death. The median survival time is 3-5 years and only around 10% survive to 10 years. 5, 6 The only disease-modifying treatment options for ALS are riluzole and edaravone. [7] [8] [9] [10] [11] [12] In contrast, MMN is associated with a normal life expectancy and has several treatment options available, [13] [14] [15] though MMN can result in progressive muscle weakness that may lead to severe disability if left untreated. 16 Early treatment with intravenous immunoglobulin (IVIg) is essential to ensure optimal treatment response and prevent progression to axonal loss. 17 It is critical therefore that MMN is correctly diagnosed as early as possible, enabling commencement of appropriate therapy to prevent permanent effects, reduce disability, and avoid the psychological distress of being misdiagnosed with ALS-a uniformly fatal illness. Unfortunately, MMN can be very difficult to diagnose in certain cases, particularly early in the disease course, and in the absence of obvious conduction block (CB) and GM1 antibodies.
This article aims to discuss the differential diagnosis of MMN and ALS, through a series of illustrative case studies.
Clinical features of multifocal motor neuropathy and amyotrophic lateral sclerosis
ALS is insidious in onset and affects more men than women. 1 Most people who develop the disease are aged between 40 and 70, with an average age of 55 at the time of diagnosis. 18 However, ALS also occurs in people in their twenties and thirties. 1 Onset is asymmetric, with weakness developing in a focal region of the face, arm or leg. Patients show signs of spasticity, rapid muscle atrophy, weakening and wasting. (Table 1) . 1, 20, 21 Like ALS, the disease has a progressive course, but progression of weakness tends to be stepwise, rather than insidious. Core clinical criteria require involvement of at least two separate motor nerves without objective sensory abnormalities, except for mild vibratory sense impairment. A characteristic electrophysiological pattern is focal slowing and CB of motor nerve fibers within nerve segments.
Cervical nerve root stimulation is also an important technique for assessing CB since approximately 13% of all CBs in MMN are proximal and may be missed with routine nerve conduction studies. 22, 23 Unlike ALS, which is believed to be caused by a combination of genetic and environmental factors, MMN clearly has an autoimmune etiology; it is associated with elevated anti-GM1 IgM levels in ~50% of patients and responds to immunomodulatory treatment. 21, [24] [25] [26] The pathophysiology of MMN and CB has been covered elsewhere and will not be reviewed here. 24 
Diagnosis of multifocal motor neuropathy and amyotrophic lateral sclerosis
A definitive diagnosis of MMN is based on core clinical criteria set out by the European Federation of Neurological Societies (EFNS)/Peripheral Nerve Society (PNS) (core, supportive and exclusion criteria in MMN diagnosis are defined by the EFNS; Table 2 ). 28 Core criteria include slowly progressive or stepwise progressive, focal, asymmetric limb weakness, in the distribution of at least two nerves, for more than one month; and no objective sensory abnormalities, except for minor vibratory abnormalities in the lower limbs.
Important features that would exclude a diagnosis of MMN include sensory loss or sensory symptoms other than mild vibratory loss in the toes, or slight paresthesia; as well as symmetric weakness at onset. 29 However, these would also be atypical for ALS. In terms of differentiation from ALS and other motor-predominant neuropathic disorders, other exclusion criteria for MMN that would help distinguish it from ALS include upper motor neuron signs and bulbar weakness. IgM anti-ganglioside GM1 antibodies are present in approximately half of patients with MMN (30-80% depending on series). 30, 31 However, they have also been associated with other immune-mediated neuropathies, non-immune-related neuropathies and even patients with ALS. [32] [33] [34] Therefore, anti-GM1 antibodies are diagnostically helpful but cannot be relied upon absolutely.
The hallmark finding of motor CB has also been left out of the EFNS diagnostic criteria, as CB in patients with otherwise typical MMN may not be detectable using standard clinical electrophysiologic testing, a test that requires considerable electrophysiological expertise. CB is defined as the failure of action potential propagation at a given site along a single axon and its presence outside the usual sites of nerve compression on nerve conduction testing constitutes the hallmark of MMN. The EFNS criteria allow for definite and probable CB. 28 Definite CB is defined as follows: US NEUROLOGY "Negative peak compound muscle action potential (CMAP) area reduction on proximal versus distal stimulation of at least 50% whatever the nerve segment length (median, ulnar, and peroneal). Negative peak CMAP amplitude on stimulation of the distal part of the segment with motor CB must be >20% of the lower limit of normal and >1 mV and increase of proximal to distal negative peak CMAP duration must be ≤30%". Probable CB is defined by: "negative peak CMAP area reduction of at least 30% over a long segment (e.g., wrist to elbow or elbow to axilla) of an upper limb nerve with increase of proximal to distal negative peak CMAP duration ≤30%" or "Negative peak CMAP area reduction of at least 50% (same as definite) with an increase of proximal to distal negative peak CMAP duration >30%". 28 Unlike axonal loss, CB will be undetectable if located at a site that is not accessible by conventional nerve conduction testing. Proximal root stimulation should be considered in these cases. 22, 23 In one study of patients with pure lower motor neuron disease without motor CB, 10% responded to IVIg therapy. 35 Therefore, the absence of CB or GM1 antibodies argues against IVIg responsiveness, but does not rule it out.
In addition to CB and other demyelinating abnormalities, there may also be evidence of motor axon loss, such as decreased distally evoked CMAP and signs of denervation and re-innervation on needle electromyography. 36 Magnetic resonance neurography is another useful diagnostic technique;
focal enlargement and increased signal intensity of the brachial plexus is seen on T2-weighted images in MMN. 37 In addition, many centers are using ultrasound to detect nerve enlargement; in a recent study, high-resolution Ultrasound has been used to differentiate MMN from other neuropathies 39 and may also be a useful tool for therapeutic monitoring.
Diagnosis of ALS employs the El Escorial criteria and Awaji algorithm. 40 According to these criteria, diagnosis of ALS requires signs of lower motor neuron degeneration by clinical, electrophysiological or neuropathologic examination, and signs of upper motor neuron degeneration by clinical examination. In addition, there must be evidence of progressive spread of signs within a region or to other regions, absence of electrophysiological evidence of other disease processes, and absence of neuroimaging evidence of other disease processes that might explain the observed clinical and electrophysiological signs.
The significant clinical overlap between these two motor processes means that misdiagnosis is common and can be difficult to avoid. It is important to identify features that help distinguish MMN from ALS.
Some of these differences have been mentioned previously but deserve further emphasis. While any body part can be affected in ALS, MMN almost always presents with wrist drop, or less frequently, foot drop. 17 As such, MMN presents in a "patchy" distribution, while ALS involves a segment such as a limb and spreads insidiously rather than in a stepwise manner. Bulbar and respiratory involvement are rarely seen in MMN but are often present in ALS. The muscle weakness associated with MMN involves less atrophy, except in severe cases or in individuals who have had the disease for many years. 41 Fasciculations occur in both MMN and ALS but are more prominent and widespread in ALS. Additionally, in ALS, fasciculations are not necessarily restricted to weak muscles. 1, 19 The absence of upper motor neuron signs is probably one of the most important clinical indicators of MMN over ALS. However, this finding must also be interpreted with caution since there are lower motor neuron ALS variants that are not uncommon and also lack upper motor neuron signs (e.g., progressive muscular atrophy). Electrophysiologically, MMN is distinguished from ALS by CB, and by extension, reduced recruitment of motor units in the absence of axonal injury. Reduced recruitment is also seen in ALS but is generally accompanied by more prominent denervation on needle electromyography. 1, 42 Diagnosis of MMN or ALS can take more than a year, and a diagnostic delay is associated with worse prognosis. In a US study of 46 patients with MMN referred to a tertiary neuromuscular center, only 6 were previously given the correct diagnosis. 2 The ratio of MMN to ALS is approximately 1 to 20, and patients with MMN are often diagnosed as having ALS. 41, 43 The correct diagnosis of MMN often requires the involvement of a neuromuscular specialist with sufficient expertise.
Treatments for multifocal motor neuropathy and evidence for their use
Current EFNS/PNS guidelines recommend IVIg as the standard, evidence-based therapy for MMN. 44 Good response to IVIg is seen in up to 80% of patients with MMN. 21, 45 Subcutaneous immunoglobulin administration has also shown efficacy in MMN and is more convenient than intravenous administration. [46] [47] [48] Further developments such as hyaluronidase-facilitated administration and concentrated formulations may facilitate subcutaneous administration. 49 Various other treatments including cyclophosphamide, rituximab, mycophenolate mofetil, beta-interferon, cyclosporine, azathioprine, and infliximab have all been used to treat MMN, but insufficient clinical trial data support their use for this indication. 50 Plasma exchange or corticosteroids are ineffective or harmful in MMN, and their use should be avoided. 51, 52 High-dose cyclosporins have also shown some efficacy but have toxicity issues, and data supporting their use are limited. 53 Rituximab has shown some efficacy in patients with MMN, but data are mixed and need confirmation in a large clinical trial. 54 Treatment options for ALS are more limited. Currently two drugs are approved that delay the progression of ALS: the anti-excitotoxic drug riluzole, which has been available for over 20 years, 8, 9 and the recently approved edaravone, an antioxidant. 55 However, edaravone has demonstrated efficacy only in a subset of patients with early stage ALS who meet specific criteria (ALS of grade 1 or 2 in the Japan ALS Severity Classification, scores of at least 2 points on all 12 items of the Revised ALS Functional Rating Scale [ALSFRS-R], forced vital capacity of 80% or more, definite or probable ALS according to the revised El Escorial criteria, and disease duration of 2 years or less). 56 
Case studies
The following series of cases are taken from the authors' experience and are typical of the challenges in differentiating MMN from ALS ( Table 3) . 
Case 2
The patient is a 70-year-old male diagnosed with ALS after developing bilateral hand weakness that left him unable to work as a sculptor. His initial complaints were of weakness of the right hand, as manifest by loss of dexterity then rapid loss of muscle bulk in his right hand and forearm.
This was followed by weakness of the right lower extremity with foot drop.
Left distal lower extremity weakness followed but remained milder than on the right. CB was not detected on initial electrodiagnostic study; only two motor nerves were studied (ulnar and median nerve on the right). Because of these symptoms and the absence of CB on electrodiagnostic study, he was given a diagnosis of ALS.
The patient was referred for another opinion when he failed to progress as was expected for his diagnosis of ALS. At the time of his re-evaluation, three of his four limbs were affected. Weakness most prominently affected his finger extensors, hand intrinsics, and thumb abduction on the right.
Affected muscle groups were wasted, but there was no sensory loss. His speech was clear without dysarthria or dysphonia. Tongue was normal without fasciculations. Muscle stretch reflexes were depressed throughout.
The presence of muscle cramping, most prominently in the legs and trunk, prompted magnetic resonance imaging of the thoracic cord, which was unrevealing for spinal cord or root enhancement. Serologic studies revealed elevated creatine kinase on two separate occasions. Ganglioside titers were negative for GM1 antibody. The diagnosis of MMN was confirmed by the finding of CB in non-compressive locations in the right ulnar, radial, and peroneal nerve. There was some active denervation in the anterior tibialis and medial gastrocnemius but this was modest and was not accompanied by evidence of significant motor unit changes. Other muscles studied were normal with the exception of pronounced recruitment 
Future perspectives
As illustrated by these case examples, there is a need for further techniques to distinguish ALS from MMN. The two conditions have been found to exhibit distinct cytokine and chemokine profiles in patients. A 2015 study (n = 56) found differences in CSF inflammatory features between patients with MMN and those with ALS; in particular, fibroblast growth factor-2 and granulocyte colony-stimulating factor levels were elevated in patients with ALS compared with those with MMN. 57 In addition, as discussed earlier, recent data has shown that nerve ultrasound has high diagnostic accuracy in the differential diagnosis of ALS and MMN, and might be superior to nerve conduction studies in the diagnosis of MMN in hospitalized patients with this differential diagnosis. 38, 58 Another recent study suggested that cervical root sonography may be a useful technique to support the diagnosis of MMN rather than ALS, even in the absence of CB. 59 A more rapid and accurate diagnosis may lead to greater numbers of patients receiving early IVIg or other MMN treatments, though the long-term outcome of more widespread early diagnosis remains unknown.
Summary and concluding remarks
The misdiagnosis of MMN as ALS is an important issue with serious clinical implications for the patient due to differences in prognosis and treatment.
In this review, some important clinical features were discussed that may help to distinguish the two disorders. In summary, the following features should alert the physician to a possible diagnosis of MMN: (i) distal upper limb involvement (although the physician should also be aware that this is a common presenting symptom of ALS); (ii) multifocal, stepwise progression in the distribution of single nerves; (iii) absence of bulbar/respiratory involvement; (iv) CB/demyelinating abnormalities on electrophysiologic study; (v) absence of upper motor neuron signs; (vi) sparse fasciculations and (vii) GM1 antibodies. 1, 20, 21, 29 However, it bears repeating that ALS variants without upper motor neuron signs can be exceedingly difficult to distinguish from immune-responsive lower motor neuron syndromes such as MMN. The presence of GM1 antibodies or CB should always prompt consideration of an IVIg trial; given that most patients will respond by 8-12 weeks of booster doses, this is appropriate given the gravity of a misdiagnosis. Similarly, in patients with pure lower motor neuron syndromes without CB or GM1 antibodies, a trial of IVIg should be considered.
